Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's future development plans, clinical trials, potential commercial success, and any financial forecasts included in this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's fil
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that their third Phase ... reduction of recurrence of hypertrophic scars following ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel ... of seed financing from friends and family investors. Proceeds ... a novel sustained-release product for ophthalmology. , "We are ... commitment to this important work," said Dr. Ken Mandell, ... many areas in which innovations in drug delivery have ...
(Date:7/29/2014)... have hurdled a number of significant technological challenges ... observing technology originally created for the James Webb ... Investigator Harvey Moseley, a scientist at NASA,s Goddard ... that electrostatically actuated microshutter arrays that is, ... are as functional as the current technology,s magnetically ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... Gov. Jim Doyle vetoed a bill that would have banned ... legislative director of Wisconsins Right to Life movement made a ... , ,We're not talking about stem cells anymore; we're talking ... cells but for organs and body parts, Right to Lifes ...
... proliferates the American landscape, Google is achieving ... not go by that Google's brand and services don't touch ... media, and business owner. , ,The seven-year-old company, which ... public just 15 months ago at $85 and closed at ...
... - Last week Gov. Jim Doyle announced a new ... to further the adoption of electronic medical records in Wisconsin. ... power of information technology at the most important point in ... a statement, citing statistics showing 30 percent of healthcare costs ...
Cached Biology Technology:Separating science fiction from reality in the human cloning debate 2Separating science fiction from reality in the human cloning debate 3Are you a citizen of the "Google Nation?" 2Are you a citizen of the "Google Nation?" 3Wisconsin pushes for adoption of electronic health records 2
(Date:7/29/2014)... sperm, bacteria and algae, propel themselves using whip-like ... of a millimetre long, function like tiny oars, ... called cilia are found on the surfaces of ... moving liquids over the cell. , Flagella ... and expel pathogens from our airways, they establish ...
(Date:7/28/2014)... communities showing signs of damage from the Deepwater Horizon oil ... the Gulf of Mexico. The discovery was made by a ... State University. A paper describing this work and additional impacts ... will be published during the last week of July 2014 ... of the National Academy of Sciences . , "The footprint ...
(Date:7/28/2014)... the United States have a circulatory problem of the ... and may even require surgery in serious cases. This ... in turn, limb amputation. , At The University of ... scientists tested a non-surgical preventative treatment in a mouse ... increased blood circulation. Their proof-of-concept study appears in ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... On the tenth anniversary of the completion of the first draft ... years to complete the Wellcome Trust today launches a project ... years. This will be one of the largest genome sequencing programmes ... one in 6,000 people in the UK. The UK10K project ...
... This release is available in German . ... Houbara bustards - a North African bird species with ... visual stimulation from attractive males of the same species ... that observed highly displaying male birds in the experiment ...
... Technology (NIST) scientists have moved a step closer to developing ... scan for thousands of disease markers and other chemical indicators ... decode the electrical signals generated by a nanoporea "gate" less ... Nanopores are not new themselves; for more than a decade, ...
Cached Biology News:Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 2Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 3Pleasing to the eye 2Pleasing to the eye 3NIST team advances in translating language of nanopores 2
UBC13 Antibody...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Phenytoin-BSA Isolated IgY DFc Drug...
Tropomyosin 4 [Tm4]...
Biology Products: